COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Lancet Rheumatol. 2022 May;4(5):e310-e313. doi: 10.1016/S2665-9913(22)00009-1. Epub 2022 Feb 8.

Laura Boekel¹, Femke Hooijberg¹, Yaëlle R Besten¹, Erik H Vogelzang², Maurice Steenhuis^{3

4}, Maureen Leeuw¹, Sadaf Atiqi¹, Ronald van Vollenhoven⁵, Willem F Lems^{1

6}, Wouter H Bos¹, Carla A Wijbrandts¹, Martijn Gerritsen¹, Charlotte Krieckaert^{5

6}, Alexandre E Voskuyl⁶, Irene E van der Horst-Bruinsma⁶, Sander W Tas⁵, Maarten Boers^{1

7}, Theo Rispens^{3

4}, Michael T Nurmohamed^{1

5}, Gertjan Wolbink^{1

3

4}

¹ Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam 1056 AB, Netherlands.
² Department of Medical Microbiology and Infection Control, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
³ Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands.
⁴ Landsteiner Laboratory Academic Medical Center, Amsterdam, Netherlands.
⁵ Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam UMC, Netherlands.
⁶ Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, Vrije Universiteit, Amsterdam UMC, Netherlands.
⁷ Department of Epidemiology and Data Science, Vrije Universiteit, Amsterdam UMC, Amsterdam, Netherlands.

No abstract available